InflaRx N.V. reported its financial results for the three and six months ended June 30, 2025, showing revenues from GOHIBIC product sales of €39 thousand for the six-month period, a decrease of €3 thousand compared to H1 2024. The company's net loss for the first six months of 2025 narrowed to €23.0 million, or €0.35 per ordinary share, compared to €23.5 million, or €0.40 per ordinary share, in H1 2024.
Research and development expenses decreased by €3.1 million to €14.2 million for the six months ended June 30, 2025, primarily due to lower third-party expenses for clinical material and manufacturing. General and administrative expenses increased by €1.5 million to €8.3 million, mainly due to higher legal, consulting, and audit expenses, and higher personnel expenses. Net cash used in operating activities decreased to €21.6 million in H1 2025 from €27.0 million in H1 2024.
As of June 30, 2025, InflaRx's total available funds amounted to approximately €53.7 million, providing a cash runway into 2027. The company expects to report topline results from the Phase 2a basket study for INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) by the end of September to early November.
In a significant collaboration update, Staidson BioPharmaceuticals announced in July 2025 that its Phase 1/2 study for anti-C5a antibody BDB-001 met its primary efficacy endpoint in AAV, demonstrating a reduction in corticosteroid use. InflaRx is entitled to mid-single-digit percentage royalties on future net sales of Staidson products containing BDB-001, including for AAV.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.